Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 10 of 10 entries
Sorted by: Best Match Show Resources per page
Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy.

Blood cancer discovery

Jeha S, Choi J, Roberts KG, Pei D, Coustan-Smith E, Inaba H, Rubnitz JE, Ribeiro RC, Gruber TA, Raimondi SC, Karol SE, Qu C, Brady SW, Gu Z, Yang JJ, Cheng C, Downing JR, Evans WE, Relling MV, Campana D, Mullighan CG, Pui CH.
PMID: 34250504
Blood Cancer Discov. 2021 Jul;2(4):326-337. doi: 10.1158/2643-3230.bcd-20-0229.

We evaluate clinical significance of recently identified subtypes of acute lymphoblastic leukemia (ALL) in 598 children treated with minimal residual disease (MRD)-directed therapy. Among the 16 B-ALL and 8 T-ALL subtypes identified by next generation sequencing,

Cite
Jeha S, Choi J, Roberts KG, et al. Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy. Blood Cancer Discov. 2021;2(4):326-337doi: 10.1158/2643-3230.bcd-20-0229.
Jeha, S., Choi, J., Roberts, K. G., Pei, D., Coustan-Smith, E., Inaba, H., Rubnitz, J. E., Ribeiro, R. C., Gruber, T. A., Raimondi, S. C., Karol, S. E., Qu, C., Brady, S. W., Gu, Z., Yang, J. J., Cheng, C., Downing, J. R., Evans, W. E., Relling, M. V., Campana, D., Mullighan, C. G., & Pui, C. H. (2021). Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy. Blood cancer discovery, 2(4), 326-337. https://doi.org/10.1158/2643-3230.bcd-20-0229
Jeha, Sima, et al. "Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy." Blood cancer discovery vol. 2,4 (2021): 326-337. doi: https://doi.org/10.1158/2643-3230.bcd-20-0229
Jeha S, Choi J, Roberts KG, Pei D, Coustan-Smith E, Inaba H, Rubnitz JE, Ribeiro RC, Gruber TA, Raimondi SC, Karol SE, Qu C, Brady SW, Gu Z, Yang JJ, Cheng C, Downing JR, Evans WE, Relling MV, Campana D, Mullighan CG, Pui CH. Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy. Blood Cancer Discov. 2021 Jul;2(4):326-337. doi: 10.1158/2643-3230.bcd-20-0229. PMID: 34250504; PMCID: PMC8265990.
Copy Download .nbib Format: NLM
New insights into methotrexate accumulation in leukemia cells .

Molecular & cellular oncology

Lopez-Lopez E, Evans WE.
PMID: 33553612
Mol Cell Oncol. 2021 Jan 11;8(1):1865086. doi: 10.1080/23723556.2020.1865086. eCollection 2021.

Measuring the amount of methotrexate polyglutamates (MTXPG) in leukemia cells after high-dose methotrexate (HDMTX) revealed that molecular subtype and lineage of acute lymphoblastic leukemia (ALL), the ratio of expression of folate influx and efflux transporters, methotrexate (MTX) infusion time,...

Cite
Lopez-Lopez E, Evans WE. New insights into methotrexate accumulation in leukemia cells . Mol Cell Oncol. 2021;8(1):1865086doi: 10.1080/23723556.2020.1865086.
Lopez-Lopez, E., & Evans, W. E. (2021). New insights into methotrexate accumulation in leukemia cells . Molecular & cellular oncology, 8(1), 1865086. https://doi.org/10.1080/23723556.2020.1865086
Lopez-Lopez, Elixabet, and Evans, William E. "New insights into methotrexate accumulation in leukemia cells ." Molecular & cellular oncology vol. 8,1 (2021): 1865086. doi: https://doi.org/10.1080/23723556.2020.1865086
Lopez-Lopez E, Evans WE. New insights into methotrexate accumulation in leukemia cells . Mol Cell Oncol. 2021 Jan 11;8(1):1865086. doi: 10.1080/23723556.2020.1865086. eCollection 2021. PMID: 33553612; PMCID: PMC7849719.
Copy Download .nbib Format: NLM
Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia.

Nature cancer

Gocho Y, Liu J, Hu J, Yang W, Dharia NV, Zhang J, Shi H, Du G, John A, Lin TN, Hunt J, Huang X, Rowland L, Shi L, Maxwell D, Smart B, Crews K, Yang W, Hagiwara K, Zhang Y, Roberts K, Wang H, Jabbour E, Stock W, Eisfelder B, Paietta E, Newman S, Roti G, Litzow M, Zhang J, Peng J, Chi H, Pounds S, Relling MV, Inaba H, Zhu X, Kornblau S, Pui CH, Konopleva M, Teachey D, Mullighan CG, Stegmaier K, Evans WE, Yu J, Yang JJ.
PMID: 34151288
Nat Cancer. 2021 Mar;2(3):284-299. doi: 10.1038/s43018-020-00167-4. Epub 2021 Jan 21.

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy, and novel therapeutics are much needed. Profiling patient leukemia' drug sensitivities

Cite
Gocho Y, Liu J, Hu J, et al. Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. Nat Cancer. 2021;2(3):284-299doi: 10.1038/s43018-020-00167-4.
Gocho, Y., Liu, J., Hu, J., Yang, W., Dharia, N. V., Zhang, J., Shi, H., Du, G., John, A., Lin, T. N., Hunt, J., Huang, X., Rowland, L., Shi, L., Maxwell, D., Smart, B., Crews, K., Yang, W., Hagiwara, K., Zhang, Y., Roberts, K., Wang, H., Jabbour, E., Stock, W., Eisfelder, B., Paietta, E., Newman, S., Roti, G., Litzow, M., Zhang, J., Peng, J., Chi, H., Pounds, S., Relling, M. V., Inaba, H., Zhu, X., Kornblau, S., Pui, C. H., Konopleva, M., Teachey, D., Mullighan, C. G., Stegmaier, K., Evans, W. E., Yu, J., & Yang, J. J. (2021). Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. Nature cancer, 2(3), 284-299. https://doi.org/10.1038/s43018-020-00167-4
Gocho, Yoshihiro, et al. "Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia." Nature cancer vol. 2,3 (2021): 284-299. doi: https://doi.org/10.1038/s43018-020-00167-4
Gocho Y, Liu J, Hu J, Yang W, Dharia NV, Zhang J, Shi H, Du G, John A, Lin TN, Hunt J, Huang X, Rowland L, Shi L, Maxwell D, Smart B, Crews K, Yang W, Hagiwara K, Zhang Y, Roberts K, Wang H, Jabbour E, Stock W, Eisfelder B, Paietta E, Newman S, Roti G, Litzow M, Zhang J, Peng J, Chi H, Pounds S, Relling MV, Inaba H, Zhu X, Kornblau S, Pui CH, Konopleva M, Teachey D, Mullighan CG, Stegmaier K, Evans WE, Yu J, Yang JJ. Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. Nat Cancer. 2021 Mar;2(3):284-299. doi: 10.1038/s43018-020-00167-4. Epub 2021 Jan 21. PMID: 34151288; PMCID: PMC8208590.
Copy Download .nbib Format: NLM
Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia.

Nature cancer

Gocho Y, Liu J, Hu J, Yang W, Dharia NV, Zhang J, Shi H, Du G, John A, Lin TN, Hunt J, Huang X, Rowland L, Shi L, Maxwell D, Smart B, Crews K, Yang W, Hagiwara K, Zhang Y, Roberts K, Wang H, Jabbour E, Stock W, Eisfelder B, Paietta E, Newman S, Roti G, Litzow M, Zhang J, Peng J, Chi H, Pounds S, Relling MV, Inaba H, Zhu X, Kornblau S, Pui CH, Konopleva M, Teachey D, Mullighan CG, Stegmaier K, Evans WE, Yu J, Yang JJ.
PMID: 34151288
Nat Cancer. 2021 Mar;2(3):284-299. doi: 10.1038/s43018-020-00167-4. Epub 2021 Jan 21.

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy, and novel therapeutics are much needed. Profiling patient leukemia' drug sensitivities

Cite
Gocho Y, Liu J, Hu J, et al. Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. Nat Cancer. 2021;2(3):284-299doi: 10.1038/s43018-020-00167-4.
Gocho, Y., Liu, J., Hu, J., Yang, W., Dharia, N. V., Zhang, J., Shi, H., Du, G., John, A., Lin, T. N., Hunt, J., Huang, X., Rowland, L., Shi, L., Maxwell, D., Smart, B., Crews, K., Yang, W., Hagiwara, K., Zhang, Y., Roberts, K., Wang, H., Jabbour, E., Stock, W., Eisfelder, B., Paietta, E., Newman, S., Roti, G., Litzow, M., Zhang, J., Peng, J., Chi, H., Pounds, S., Relling, M. V., Inaba, H., Zhu, X., Kornblau, S., Pui, C. H., Konopleva, M., Teachey, D., Mullighan, C. G., Stegmaier, K., Evans, W. E., Yu, J., & Yang, J. J. (2021). Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. Nature cancer, 2(3), 284-299. https://doi.org/10.1038/s43018-020-00167-4
Gocho, Yoshihiro, et al. "Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia." Nature cancer vol. 2,3 (2021): 284-299. doi: https://doi.org/10.1038/s43018-020-00167-4
Gocho Y, Liu J, Hu J, Yang W, Dharia NV, Zhang J, Shi H, Du G, John A, Lin TN, Hunt J, Huang X, Rowland L, Shi L, Maxwell D, Smart B, Crews K, Yang W, Hagiwara K, Zhang Y, Roberts K, Wang H, Jabbour E, Stock W, Eisfelder B, Paietta E, Newman S, Roti G, Litzow M, Zhang J, Peng J, Chi H, Pounds S, Relling MV, Inaba H, Zhu X, Kornblau S, Pui CH, Konopleva M, Teachey D, Mullighan CG, Stegmaier K, Evans WE, Yu J, Yang JJ. Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. Nat Cancer. 2021 Mar;2(3):284-299. doi: 10.1038/s43018-020-00167-4. Epub 2021 Jan 21. PMID: 34151288; PMCID: PMC8208590.
Copy Download .nbib Format: NLM
Identification of small molecules that mitigate vincristine-induced neurotoxicity while sensitizing leukemia cells to vincristine.

Clinical and translational science

Diouf B, Wing C, Panetta JC, Eddins D, Lin W, Yang W, Fan Y, Pei D, Cheng C, Delaney SM, Zhang W, Bonten EJ, Crews KR, Paugh SW, Li L, Freeman BB, Autry RJ, Beard JA, Ferguson DC, Janke LJ, Ness KK, Chen T, Zakharenko SS, Jeha S, Pui CH, Relling MV, Eileen Dolan M, Evans WE.
PMID: 33742760
Clin Transl Sci. 2021 Jul;14(4):1490-1504. doi: 10.1111/cts.13012. Epub 2021 May 31.

Vincristine (VCR) is one of the most widely prescribed medications for treating solid tumors and acute lymphoblastic leukemia (ALL) in children and adults. However, its major dose-limiting toxicity is peripheral neuropathy that can disrupt curative therapy. Peripheral neuropathy can...

Cite
Diouf B, Wing C, Panetta JC, et al. Identification of small molecules that mitigate vincristine-induced neurotoxicity while sensitizing leukemia cells to vincristine. Clin Transl Sci. 2021;14(4):1490-1504doi: 10.1111/cts.13012.
Diouf, B., Wing, C., Panetta, J. C., Eddins, D., Lin, W., Yang, W., Fan, Y., Pei, D., Cheng, C., Delaney, S. M., Zhang, W., Bonten, E. J., Crews, K. R., Paugh, S. W., Li, L., Freeman, B. B., Autry, R. J., Beard, J. A., Ferguson, D. C., Janke, L. J., Ness, K. K., Chen, T., Zakharenko, S. S., Jeha, S., Pui, C. H., Relling, M. V., Eileen Dolan, M., & Evans, W. E. (2021). Identification of small molecules that mitigate vincristine-induced neurotoxicity while sensitizing leukemia cells to vincristine. Clinical and translational science, 14(4), 1490-1504. https://doi.org/10.1111/cts.13012
Diouf, Barthelemy, et al. "Identification of small molecules that mitigate vincristine-induced neurotoxicity while sensitizing leukemia cells to vincristine." Clinical and translational science vol. 14,4 (2021): 1490-1504. doi: https://doi.org/10.1111/cts.13012
Diouf B, Wing C, Panetta JC, Eddins D, Lin W, Yang W, Fan Y, Pei D, Cheng C, Delaney SM, Zhang W, Bonten EJ, Crews KR, Paugh SW, Li L, Freeman BB, Autry RJ, Beard JA, Ferguson DC, Janke LJ, Ness KK, Chen T, Zakharenko SS, Jeha S, Pui CH, Relling MV, Eileen Dolan M, Evans WE. Identification of small molecules that mitigate vincristine-induced neurotoxicity while sensitizing leukemia cells to vincristine. Clin Transl Sci. 2021 Jul;14(4):1490-1504. doi: 10.1111/cts.13012. Epub 2021 May 31. PMID: 33742760; PMCID: PMC8301581.
Copy Download .nbib Format: NLM
New insights into methotrexate accumulation in leukemia cells .

Molecular & cellular oncology

Lopez-Lopez E, Evans WE.
PMID: 33553612
Mol Cell Oncol. 2021 Jan 11;8(1):1865086. doi: 10.1080/23723556.2020.1865086. eCollection 2021.

Measuring the amount of methotrexate polyglutamates (MTXPG) in leukemia cells after high-dose methotrexate (HDMTX) revealed that molecular subtype and lineage of acute lymphoblastic leukemia (ALL), the ratio of expression of folate influx and efflux transporters, methotrexate (MTX) infusion time,...

Cite
Lopez-Lopez E, Evans WE. New insights into methotrexate accumulation in leukemia cells . Mol Cell Oncol. 2021;8(1):1865086doi: 10.1080/23723556.2020.1865086.
Lopez-Lopez, E., & Evans, W. E. (2021). New insights into methotrexate accumulation in leukemia cells . Molecular & cellular oncology, 8(1), 1865086. https://doi.org/10.1080/23723556.2020.1865086
Lopez-Lopez, Elixabet, and Evans, William E. "New insights into methotrexate accumulation in leukemia cells ." Molecular & cellular oncology vol. 8,1 (2021): 1865086. doi: https://doi.org/10.1080/23723556.2020.1865086
Lopez-Lopez E, Evans WE. New insights into methotrexate accumulation in leukemia cells . Mol Cell Oncol. 2021 Jan 11;8(1):1865086. doi: 10.1080/23723556.2020.1865086. eCollection 2021. PMID: 33553612; PMCID: PMC7849719.
Copy Download .nbib Format: NLM
Pharmacogenomics of adverse effects of anti-leukemic agents in children.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG

Relling MV.
PMID: 23118655
J Pediatr Pharmacol Ther. 2012 Jan;17(1):7-11. doi: 10.5863/1551-6776-17.1.7.

No abstract available.

Cite
Relling MV. Pharmacogenomics of adverse effects of anti-leukemic agents in children. J Pediatr Pharmacol Ther. 2012;17(1):7-11doi: 10.5863/1551-6776-17.1.7.
Relling, M. V. (2012). Pharmacogenomics of adverse effects of anti-leukemic agents in children. The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 17(1), 7-11. https://doi.org/10.5863/1551-6776-17.1.7
Relling, Mary V. "Pharmacogenomics of adverse effects of anti-leukemic agents in children." The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG vol. 17,1 (2012): 7-11. doi: https://doi.org/10.5863/1551-6776-17.1.7
Relling MV. Pharmacogenomics of adverse effects of anti-leukemic agents in children. J Pediatr Pharmacol Ther. 2012 Jan;17(1):7-11. doi: 10.5863/1551-6776-17.1.7. PMID: 23118655; PMCID: PMC3428190.
Copy Download .nbib Format: NLM
Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy.

Blood cancer discovery

Jeha S, Choi J, Roberts KG, Pei D, Coustan-Smith E, Inaba H, Rubnitz JE, Ribeiro RC, Gruber TA, Raimondi SC, Karol SE, Qu C, Brady SW, Gu Z, Yang JJ, Cheng C, Downing JR, Evans WE, Relling MV, Campana D, Mullighan CG, Pui CH.
PMID: 34250504
Blood Cancer Discov. 2021 Jul;2(4):326-337. doi: 10.1158/2643-3230.BCD-20-0229.

We evaluate clinical significance of recently identified subtypes of acute lymphoblastic leukemia (ALL) in 598 children treated with minimal residual disease (MRD)-directed therapy. Among the 16 B-ALL and 8 T-ALL subtypes identified by next generation sequencing,

Cite
Jeha S, Choi J, Roberts KG, et al. Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy. Blood Cancer Discov. 2021;2(4):326-337doi: 10.1158/2643-3230.BCD-20-0229.
Jeha, S., Choi, J., Roberts, K. G., Pei, D., Coustan-Smith, E., Inaba, H., Rubnitz, J. E., Ribeiro, R. C., Gruber, T. A., Raimondi, S. C., Karol, S. E., Qu, C., Brady, S. W., Gu, Z., Yang, J. J., Cheng, C., Downing, J. R., Evans, W. E., Relling, M. V., Campana, D., Mullighan, C. G., & Pui, C. H. (2021). Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy. Blood cancer discovery, 2(4), 326-337. https://doi.org/10.1158/2643-3230.BCD-20-0229
Jeha, Sima, et al. "Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy." Blood cancer discovery vol. 2,4 (2021): 326-337. doi: https://doi.org/10.1158/2643-3230.BCD-20-0229
Jeha S, Choi J, Roberts KG, Pei D, Coustan-Smith E, Inaba H, Rubnitz JE, Ribeiro RC, Gruber TA, Raimondi SC, Karol SE, Qu C, Brady SW, Gu Z, Yang JJ, Cheng C, Downing JR, Evans WE, Relling MV, Campana D, Mullighan CG, Pui CH. Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy. Blood Cancer Discov. 2021 Jul;2(4):326-337. doi: 10.1158/2643-3230.BCD-20-0229. PMID: 34250504; PMCID: PMC8265990.
Copy Download .nbib Format: NLM
Treatment response and outcome of children with T-cell acute lymphoblastic leukemia expressing the gamma-delta T-cell receptor.

Oncoimmunology

Pui CH, Pei D, Cheng C, Tomchuck SL, Evans SN, Inaba H, Jeha S, Raimondi SC, Choi JK, Thomas PG, Dallas MH.
PMID: 31413907
Oncoimmunology. 2019 May 17;8(8):1599637. doi: 10.1080/2162402X.2019.1599637. eCollection 2019.

T-cell malignancies expressing the γδ T-cell receptor (TCR) are often associated with poor prognosis. Here, we determined the clinical outcome of pediatric patients with T-cell acute lymphoblastic leukemia (T-ALL) expressing the γδ TCR. Of 100 newly diagnosed T-ALL patients,...

Cite
Pui CH, Pei D, Cheng C, et al. Treatment response and outcome of children with T-cell acute lymphoblastic leukemia expressing the gamma-delta T-cell receptor. Oncoimmunology. 2019;8(8):1599637doi: 10.1080/2162402X.2019.1599637.
Pui, C. H., Pei, D., Cheng, C., Tomchuck, S. L., Evans, S. N., Inaba, H., Jeha, S., Raimondi, S. C., Choi, J. K., Thomas, P. G., & Dallas, M. H. (2019). Treatment response and outcome of children with T-cell acute lymphoblastic leukemia expressing the gamma-delta T-cell receptor. Oncoimmunology, 8(8), 1599637. https://doi.org/10.1080/2162402X.2019.1599637
Pui, Ching-Hon, et al. "Treatment response and outcome of children with T-cell acute lymphoblastic leukemia expressing the gamma-delta T-cell receptor." Oncoimmunology vol. 8,8 (2019): 1599637. doi: https://doi.org/10.1080/2162402X.2019.1599637
Pui CH, Pei D, Cheng C, Tomchuck SL, Evans SN, Inaba H, Jeha S, Raimondi SC, Choi JK, Thomas PG, Dallas MH. Treatment response and outcome of children with T-cell acute lymphoblastic leukemia expressing the gamma-delta T-cell receptor. Oncoimmunology. 2019 May 17;8(8):1599637. doi: 10.1080/2162402X.2019.1599637. eCollection 2019. PMID: 31413907; PMCID: PMC6682360.
Copy Download .nbib Format: NLM
Individual prediction of nonadherence to oral mercaptopurine in children with acute lymphoblastic leukemia: Results from COG AALL03N1.

Cancer

Hoppmann AL, Chen Y, Landier W, Hageman L, Evans WE, Wong FL, Relling MV, Bhatia S.
PMID: 34161608
Cancer. 2021 Oct 15;127(20):3832-3839. doi: 10.1002/cncr.33760. Epub 2021 Jun 23.

BACKGROUND: Poor mercaptopurine (6MP) adherence (mean adherence rate < 90%) increases the relapse risk among children with acute lymphoblastic leukemia (ALL). 6MP adherence remains difficult to measure in real time. Easily measured patient-level factors could identify patients at risk...

Cite
Hoppmann AL, Chen Y, Landier W, et al. Individual prediction of nonadherence to oral mercaptopurine in children with acute lymphoblastic leukemia: Results from COG AALL03N1. Cancer. 2021;127(20):3832-3839doi: 10.1002/cncr.33760.
Hoppmann, A. L., Chen, Y., Landier, W., Hageman, L., Evans, W. E., Wong, F. L., Relling, M. V., & Bhatia, S. (2021). Individual prediction of nonadherence to oral mercaptopurine in children with acute lymphoblastic leukemia: Results from COG AALL03N1. Cancer, 127(20), 3832-3839. https://doi.org/10.1002/cncr.33760
Hoppmann, Anna L, et al. "Individual prediction of nonadherence to oral mercaptopurine in children with acute lymphoblastic leukemia: Results from COG AALL03N1." Cancer vol. 127,20 (2021): 3832-3839. doi: https://doi.org/10.1002/cncr.33760
Hoppmann AL, Chen Y, Landier W, Hageman L, Evans WE, Wong FL, Relling MV, Bhatia S. Individual prediction of nonadherence to oral mercaptopurine in children with acute lymphoblastic leukemia: Results from COG AALL03N1. Cancer. 2021 Oct 15;127(20):3832-3839. doi: 10.1002/cncr.33760. Epub 2021 Jun 23. PMID: 34161608; PMCID: PMC8478829.
Copy Download .nbib Format: NLM
Showing 1 to 10 of 10 entries